Pfizer Stock Price, News & Analysis

Pfizer announced plans to exit its 32% ownership interest in Haleon, the new standalone company formed post-GSK demerger. This move aims to maximize shareholder value. The demerger, involving GSK transferring approximately 80% of its consumer healthcare business to GSK shareholders, will be completed by July 2022. Haleon will also pursue a listing on the New York Stock Exchange. Key legal and financial advisors, including Morgan Stanley and Guggenheim Securities, are engaged in the process. This strategic decision aligns with Pfizer's focus on innovative medicines and vaccines.

Pfizer Inc. (NYSE: PFE) will host a live webcast on June 6, 2022 at 3:45 p.m. EDT featuring Angela Hwang and Aamir Malik discussing initiatives on expanding access and affordability for Pfizer’s medicines and vaccines. Investors can register and access the webcast via Pfizer's investor website. A transcript will be available within 24 hours post-event. The company emphasizes its commitment to quality healthcare and responsible collaboration worldwide.

Pfizer (NYSE: PFE) announced that its investigational therapy ervogastat (PF-06865571) and clesacostat (PF-05221304) for treating non-alcoholic steatohepatitis (NASH) with liver fibrosis has received Fast Track designation from the FDA. This designation aims to expedite the review of therapies addressing unmet medical needs. Phase 2a trial results showed a significant reduction in liver fat and a favorable safety profile. Pfizer is also conducting an ongoing Phase 2 trial (NCT04321031), with results expected in 2024, which will inform potential Phase 3 development.

Pfizer Inc. (NYSE: PFE) will host a webcast featuring CEO Albert Bourla at the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1, 2022, at 9:00 a.m. EDT. Interested parties can access the live event and subsequent replay on Pfizer's investor website, available at www.pfizer.com/investors, starting today. A transcript and replay will be accessible for 90 days following the event. Pfizer emphasizes its commitment to improving patient health through innovative therapies and ongoing support for affordable healthcare worldwide.

Pfizer has launched 'An Accord for a Healthier World', aiming to provide patent-protected medicines and vaccines on a not-for-profit basis to 1.2 billion people in 45 lower-income countries. This initiative includes partnerships with five initial countries: Rwanda, Ghana, Malawi, Senegal, and Uganda. Key objectives include improving healthcare infrastructure and access to essential medicines to reduce health inequities. Pfizer will offer 23 medicines and vaccines, with future products added to the Accord as they become available.

Pfizer announces the launch of ‘An Accord for a Healthier World’, providing its patented medicines and vaccines on a not-for-profit basis to 1.2 billion people across 45 lower-income countries. The initiative aims to address health inequities and includes collaboration with health officials from Rwanda, Ghana, Malawi, Senegal, and Uganda. Pfizer commits to making available 23 medicines and vaccines and streamlining regulatory pathways to improve access. The Accord emphasizes global health equity, with potential impacts on the lives of nearly one million annually in these regions.

Pfizer Inc. (NYSE: PFE) announced successful results from two pivotal studies of etrasimod for moderately-to-severely active ulcerative colitis (UC) at Digestive Disease Week 2022. Both Phase 3 trials, ELEVATE UC 52 and ELEVATE UC 12, met all primary and key secondary endpoints, showing significant improvement in clinical remission rates. In ELEVATE UC 52, 32.1% of patients on etrasimod achieved clinical remission at week 52 versus 6.7% for placebo. Safety profiles were consistent with previous studies. Regulatory filings are anticipated later this year.

Pfizer and BioNTech announced that their COVID-19 vaccine, with a third 3-µg dose for children under 5, met all immunobridging criteria for Emergency Use Authorization. A trial involving 1,678 children showed a favorable safety profile similar to placebo, with vaccine efficacy of 80.3% against symptomatic COVID-19 during the Omicron variant's surge. The companies plan to submit updated data to the FDA and other global regulators soon. The trial aims to provide strong protection against COVID-19 in young children, building on previous successful adult and adolescent studies.

The U.S. FDA has expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to include a booster dose for children aged 5 to 11. This booster, a 10-µg dose, can be administered at least five months after the second dose. Over 8 million children in this age group have completed the primary series. Data from clinical trials showed a strong immune response against both the Omicron variant and the wild-type virus, with no new safety issues reported.